LEGN
HealthcareLegend Biotech Corporation · Biotechnology · $5B
What is Legend Biotech Corporation?
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies for cancer. Headquartered in Somerset, New Jersey, it operates across the United States, China, and international markets.
Legend Biotech discovers and develops CAR-T cell therapies — a form of immunotherapy that engineers a patient's own immune cells to target cancer. Its lead program targets multiple myeloma in collaboration with Janssen Biotech. The company also advances earlier-stage programs for gastric cancer, T-cell lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia, alongside preclinical work in solid tumors and infectious diseases.
Legend Biotech was founded in 2014 and is headquartered in Somerset, New Jersey.
- Ciltacabtagene autoleucel — CAR-T therapy for multiple myeloma, partnered with Janssen Biotech
- LCAR-B38M — lead chimeric antigen receptor candidate targeting multiple myeloma
- CAR-T candidates targeting CD19, CD20, and CD22 for blood cancers
- Autologous cell therapy programs in Phase I for gastric cancer and T-cell lymphoma
- Preclinical pipeline addressing solid tumors and infectious diseases
Is LEGN a Good Stock to Buy?
UQS Score rates LEGN as Below Average overall, reflecting a profile where exceptional growth potential is tempered by meaningful quality and financial concerns.
The Growth pillar stands out as the clearest bright spot — Legend Biotech's expanding CAR-T pipeline and its commercialization partnership with Janssen Biotech position it among the more growth-oriented names in the clinical-stage biotech space. Valuation also registers as Good relative to peers, suggesting the market has already priced in considerable uncertainty.
The Quality pillar is rated Weak, consistent with a pre-profitability company still investing heavily in clinical development. Investors should weigh the inherent binary risks of a pipeline-dependent business model.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LEGN pay dividends?
No — Legend Biotech Corporation does not currently pay a dividend.
Legend Biotech does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Available capital is directed toward funding clinical trials, pipeline expansion, and commercialization activities. Income-focused investors should look elsewhere; growth-oriented investors may find the reinvestment rationale consistent with the company's development stage.
When does LEGN report earnings?
Legend Biotech reports financial results on a quarterly cadence, consistent with US-listed equities.
As a clinical-stage company, quarterly results are driven more by pipeline milestones, collaboration revenue from Janssen, and operating expense trends than by traditional profitability metrics. Revenue recognition and cash runway updates tend to be the focal points for investors each reporting period.
For the most recent quarter's results and guidance, visit Legend Biotech's investor relations page directly.
LEGN Price History
-35.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Legend Biotech Corporation?
Based on Legend Biotech Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LEGN Long-term Outlook
Legend Biotech's Growth pillar is rated Strong, reflecting meaningful near-term catalysts tied to the continued rollout of its multiple myeloma therapy and advancing pipeline programs. However, the Weak Quality pillar signals that the path to sustainable profitability remains uncertain. The Neutral Risk rating suggests the company carries typical clinical-stage risks — trial outcomes, regulatory timelines, and partnership dynamics — without extreme outlier exposure on either end.
Growth drivers
- Expanding commercial uptake of ciltacabtagene autoleucel through the Janssen partnership
- Pipeline progression across multiple blood cancer indications in Phase I and earlier stages
- Potential label expansions and new indications for existing CAR-T programs
Key risks
- Clinical trial failures or regulatory setbacks could materially reset the growth narrative
- Heavy reliance on the Janssen collaboration for near-term revenue and commercialization
- Ongoing cash consumption typical of pre-profitability biotech development
LEGN vs Peers
Legend Biotech operates in a competitive clinical-stage and specialty biopharma landscape alongside companies pursuing differentiated therapeutic approaches.
NewAmsterdam focuses on cardiovascular metabolic disease rather than oncology, representing a distinct therapeutic area from Legend's CAR-T cancer programs.
ACADIA targets central nervous system disorders, giving it a different risk and revenue profile compared to Legend's oncology-focused cell therapy pipeline.
Viking Therapeutics concentrates on metabolic and endocrine diseases, contrasting with Legend's specialization in CAR-T immunotherapy for blood cancers.
Frequently Asked Questions
What does Legend Biotech do?
Legend Biotech develops CAR-T cell therapies — treatments that reprogram a patient's immune cells to attack cancer. Its primary focus is multiple myeloma, with additional programs targeting other blood cancers and early-stage work in solid tumors. The company collaborates with Janssen Biotech on its most advanced program.
Does LEGN pay dividends?
No, Legend Biotech does not currently pay a dividend. As a clinical-stage biopharmaceutical company, it reinvests available resources into research, clinical trials, and commercialization efforts. Dividend payments are not typical for companies at this stage of development.
When does LEGN report earnings?
Legend Biotech reports on a quarterly cadence, standard for US-listed companies. Specific upcoming dates are not covered by our data source. Check Legend Biotech's investor relations page for the current earnings calendar.
Is LEGN a good stock to buy?
UQS Score rates LEGN as Below Average overall. The Growth pillar is Strong, reflecting a compelling pipeline and commercial partnership, but the Weak Quality pillar highlights the financial risks common to pre-profitability biotechs. Whether it fits a portfolio depends on an investor's risk tolerance and time horizon.
Is LEGN overvalued?
The UQS Valuation pillar for LEGN is rated Good, suggesting the current price reflects a reasonable level of risk relative to peers. Clinical-stage biotechs are inherently difficult to value given binary pipeline outcomes, so valuation should be considered alongside the Risk and Quality pillars.
How does LEGN compare to its competitors?
Legend Biotech is differentiated by its focus on CAR-T cell therapy for oncology — a specialized and capital-intensive field. Peers like ACADIA and Viking Therapeutics operate in entirely different therapeutic areas, making direct comparisons more about risk profile and development stage than head-to-head product competition.
What is LEGN's market cap bracket?
Legend Biotech is classified as a mid-cap company. This places it in a range where it has more resources than smaller clinical-stage peers but still carries meaningful development and commercialization risk compared to large or mega-cap pharmaceutical companies.
Who founded Legend Biotech?
Legend Biotech was founded in 2014. It is a subsidiary of Genscript Biotech Corporation. For detailed founding history and leadership background, the company's official investor relations materials are the most reliable source.
Is LEGN a long-term quality investment?
From a quality indicator perspective, LEGN's UQS profile is mixed. The Strong Growth pillar points to long-term pipeline potential, but the Weak Quality pillar reflects the financial fragility typical of clinical-stage companies. Long-term conviction here depends heavily on pipeline execution and partnership outcomes.
What is the main competitive advantage of Legend Biotech?
Legend Biotech's primary differentiation lies in its CAR-T platform and its collaboration with Janssen Biotech, a major pharmaceutical company. This partnership provides commercial infrastructure and resources that many clinical-stage biotechs lack. The UQS Moat pillar is rated Neutral, reflecting early but not yet entrenched competitive positioning.
What sector does LEGN belong to?
Legend Biotech operates in the Healthcare sector, specifically within the clinical-stage biopharmaceutical and cell therapy space. Investors can explore other [healthcare sector stocks](/sector/healthcare) on UQS Score to compare quality profiles across the industry.
Unlock Full LEGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare LEGN against peers with side-by-side scoring
- ✓See Quality and Risk breakdowns behind the overall rating
- ✓Track pipeline-stage companies across the healthcare sector
- ✓Get the complete analyst-grade view with a Pro membership
Pro Analysis
LEGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 48.4 | 15.0 | 42.0 | 85.0 | 52.4 | 62.3 | -0.2 |
| May 21, 2026 | 48.6 | 15.0 | 42.0 | 85.0 | 52.4 | 63.0 | +1.1 |
| May 14, 2026 | 47.5 | 15.0 | 42.0 | 85.0 | 45.2 | 63.1 | -0.5 |
| May 12, 2026 | 48.0 | 15.0 | 42.0 | 85.0 | 45.2 | 66.5 | +0.3 |
| May 11, 2026 | 47.7 | 15.0 | 42.0 | 85.0 | 45.2 | 64.6 | +0.1 |
| May 7, 2026 | 47.6 | 15.0 | 42.0 | 85.0 | 45.2 | 64.0 | -0.7 |
| May 3, 2026 | 48.3 | 15.0 | 42.0 | 85.0 | 45.2 | 68.2 | +0.1 |
| Apr 26, 2026 | 48.2 | 15.0 | 42.0 | 85.0 | 45.2 | 67.9 | -0.4 |
| Apr 19, 2026 | 48.6 | 15.0 | 42.0 | 85.0 | 45.2 | 70.7 | -0.8 |
| Apr 14, 2026 | 49.4 | 15.0 | 42.0 | 85.0 | 45.2 | 75.7 | +0.1 |
LEGN — Pillar Breakdown
Quality
— 15.0/100 (25%)Legend Biotech Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.0/100 (20%)Legend Biotech Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 52.4/100 (15%)Legend Biotech Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 62.3/100 (15%)Legend Biotech Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 42/100 (25%)Legend Biotech Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LEGN.
Score Composition
Financial Data
More Stock Analysis
How is the LEGN UQS Score Calculated?
The UQS (Unified Quality Score) for Legend Biotech Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Legend Biotech Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Legend Biotech Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.